Atogepant Enhances Botox for Chronic Migraine Relief

Research Summary

A recent study published in Cephalalgia explores the effects of combining atogepant with onabotulinumtoxinA for chronic migraine prevention. Conducted over 24 weeks with 75 participants, the research found that adding atogepant to a stable dose of onabotulinumtoxinA resulted in a significant reduction in migraine days. Participants experienced an average decrease of 7 days per month, with responder rates of 54% achieving at least a 50% reduction and 31% achieving a 75% reduction in migraine days. The treatment was generally well-tolerated, with common side effects including constipation (16%) and nausea (13%). This combination treatment shows promise for managing chronic migraines.

Study Details

📄 Title: Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.

👥 Research Team: Rothrock J et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2026 Apr

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.